Heather Hampel,Rachel Pearlman,Albert de la Chapelle,Colin C Pritchard,Weiqiang Zhao,Dan Jones,Ahmet Yilmaz,Wei Chen,Wendy L Frankel,Adrian A Suarez,Casey Cosgrove,Floor Backes,Larry Copeland,Jeffrey Fowler,David O'Malley,Ritu Salani,Joseph P McElroy,Peter P Stanich,Paul Goodfellow,David E Cohn,Colin C. Pritchard,Wendy L. Frankel,Adrian A. Suarez,Joseph P. McElroy,Peter P. Stanich,David E. Cohn

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Lynch syndrome is the most common cause of inherited endometrial cancer, attributable to germline pathogenic variants (PV) in mismatch repair (MMR) genes. Tumor microsatellite instability (MSI-high) and MMR IHC abnormalities are characteristics of Lynch syndrome. Double somatic MMR gene PV also cause MSI-high endometrial cancers. The aim of this study was to determine the relative frequency of Lynch syndrome and double somatic MMR PV.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>341 endometrial cancer patients enrolled in the Ohio Colorectal Cancer Prevention Initiative at The Ohio State University Comprehensive Cancer Center from 1/1/13–12/31/16. All tumors underwent immunohistochemical (IHC) staining for the four MMR proteins, MSI testing, and <em>MLH1</em> methylation testing if the tumor was MMR-deficient (dMMR). Germline genetic testing for Lynch syndrome was undertaken for all cases with dMMR tumors lacking <em>MLH1</em> methylation. Tumor sequencing followed if a germline MMR gene PV was not identified.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Twenty-seven percent (91/341) of tumors were either MSI-high or had abnormal IHC indicating dMMR. As expected, most dMMR tumors had <em>MLH1</em> methylation; (69, 75.8% of the dMMR cases; 20.2% of total). Among the 22 (6.5%) cases with dMMR not explained by methylation, 10 (2.9% of total) were found to have Lynch syndrome (6 <em>MSH6</em>, 3 <em>MSH2</em>, 1 <em>PMS2</em>). Double somatic MMR PV accounted for the remaining 12 dMMR cases (3.5% of total).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Since double somatic MMR gene PV are as common as Lynch syndrome among endometrial cancer patients, paired tumor and germline testing for patients with non-methylated dMMR tumor may be the most efficient approach for LS screening.</p>

Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients